Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Janssen Pharmaceutica Inc.

Latest From Janssen Pharmaceutica Inc.

5 Dealmaking Trends To Watch In 2022

2021 was an unusual but exciting year for dealmaking in the biopharma industry. How will 2022 compare?

Deals Companies

Biological E's COVID-19 Vaccine Launched, MD Says India Supplies To WHO Not Under Threat

Despite Indian companies not being able to honor COVID-19 vaccine export commitments, Biological E’s MD believes mitigating circumstances mean relations with the agency won’t be damaged. Meanwhile, Corbevax is being used in India's immunization program and a tech transfer for Johnson & Johnson’s COVID-19 vaccine is going ahead.

Commercial Business Strategies

J&J’s Gorsky Puts Spotlight On Big Picture Potential Of Asia, New Technologies

Keep your eyes on Asia, both for groundbreaking innovation and huge market opportunities, says Alex Gorsky, executive chairman of Johnson & Johnson. He also outlines exciting possibilities as biology and chemistry are being “fundamentally digitized.”

Research & Development Asia Pacific

Biosimilar Use, Cost Trends In Medicare Part B Will Be Examined By HHS Inspector General

If study finds biosimilar uptake in the Part B program is lagging, it may inform policy changes to encourage gains. On the other hand,  the latest biosimilars trend reports from Cardinal Health and Amgen show follow-ons are controlling share in some markets for physician-administered drugs and savings are adding up.

Biosimilars Market Access
See All

Company Information

  • Industry
  • Pharmaceuticals